Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors

Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors (Cardiac-CV)

Status

Suspended

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01740739

Acronym

Cardiac-CV

Enrollment

Registered

2012-12-04

Start date

2012-11-30

Completion date

2013-06-30

Last updated

2013-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Coronary Artery Disease

Keywords

Health Risk Appraisal, HCardiac Risk Factors

Brief summary

The objective of this study is to explore the relationship between the ClearView scan results and a variety of cardiovascular risk indicators such as the Coronary Calcium Score, Framingham Risk Factors, Reynolds Risk Score, and biomarkers of inflammation. The ClearView device is a bio-electrographic tool that may assist medical professionals in rapid assessment of the systemic origin of the patient's presenting symptom(s). The ClearView is a potentially valuable resource that may benefit a physician's office by offering expedited differentiation capabilities. The subsequent results have the potential to include more data that would allow rapid patient diagnosis, triage, and treatment; optimized precious resource expenditure (nursing, physician, etc.); lower costs to facility, patient and insurance company; and decreased office wait time.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Sex: Male or Female * Age range: 18 to 85 * Patients who are recommended for and who have had a cardiac CT study that produces a Coronary Calcium Score within 30 days prior to the ClearView Scan or plan to have the CT within 14 days after the ClearView Scan. * Patients who have had a blood test resulting in hs-CRP, fasting lipid panel and MPO results within 6 months prior to the ClearView Scan or plan to have the tests done within 14 days after the ClearView Scan. * The patient or legal representative is able to understand and provide signed consent for the procedure.

Exclusion criteria

* Patients with pacemakers or another implanted electrical device, such as an automatic internal cardiac defibrillator. * Patients connected to an electrical device that cannot be removed or temporarily powered off (i.e. monitor) during subject testing with the ClearView Device * Vulnerable populations * Patients actively being treated for cancer or with a previous diagnosis of cancer that required chemotherapy, radiation therapy or hormonal therapy. * Patients missing all or any part of a fingertip (excluding fingernail). * Patients with involuntary hand tremors /shaking of the hands that may prevent clear imaging.

Design outcomes

Primary

Measure	Time frame	Description
Association of ClearView scan with cardiovascular risk indicators	Single Study Vist, no follow-up.	Statistical agreement will be assessed between the ClearView Response result and the results of the Corinary Calcium Score, Inflammatory biomarkers, lipid panel results and cardiovascular risk indicators as reported by the medical exam, on a per-subject basis.

Countries

United States

Outcome results